TriangleNemtabrutinib (NCT07194980)
Nemtabrutinib trial for Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT07194980). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who qualify for standard lisocabtagene maraleucel. Richter transformation is excluded.
The idea: add oral nemtabrutinib, which blocks BTK survival signals, to CAR T-cell treatment. Collected immune cells are modified to recognize CD19 on cancer cells. Cyclophosphamide and fludarabine prepare patients before the cell infusion. Nemtabrutinib pauses during this preparation. Researchers assess complete responses.
This phase 2 study plans 20 patients. Jennifer Huang leads at Fred Hutch/University of Washington in Seattle, the sole recruiting US location.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.